Back Hall, K (11 Jan 2022) 'The discovery of insulin: a story of monstrous egos and toxic rivalries', The Conversation
Saxenda 3 mg daily for weight management): Proven efficacy with 5-8% weight reduction and cardiovascular outcome benefits in the LEADER trial Dulaglutide (Trulicity 0.75-4.5 mg weekly): Convenient once-weekly dosing with demonstrated cardiovascular benefit in the REWIND trial Tirzepatide (Mounjaro for diabetes
Supporting your body during the entire weight loss journey The bigger picture extends beyond hair
Association between exenatide use and incidence of Alzheimers disease
Buyer Takeaway: Both GLP-1 and GLP-1+GIP options work through appetite-regulating mechanisms with different pharmacological breadth
W., Hviid, A., Eliasson, B., Hveem, K., Melbye, M., Gudbjrnsdottir, S., Ueda, P., & the Nordic GLP-1RA Thyroid Cancer Collaboration